Loading stock data…
Amneal Pharmaceuticals, Inc. (AMRX)
$17.44-0.43 (-2.41%)
Pre-Market$17.36-0.08 (-0.46%)· Last close Sep 4
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amneal Pharmaceuticals, Inc. in the Healthcare sector is trading at $17.44 with a market capitalization of $6.3B. Wall Street consensus targets $21.00 (5 analysts), implying a +20.4% move over the next 12 months. The stock is currently near its 52-week high of $19.26, remaining 21.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $796.20M↑ | $722.52M↓ | $814.32M↑ | $784.51M↑ | $724.51M |
| Gross Profit | $334.51M↑ | $320.11M↑ | $297.19M↑ | $273.97M↓ | $286.25M |
| Operating Income | $145.98M↓ | $148.27M↑ | $114.50M↑ | $70.49M↓ | $112.01M |
| Net Income | $57.66M↓ | $62.26M↑ | $35.08M↑ | $2.37M↓ | $22.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.86
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
476.51%
Volume
Today's trading volume
1.44M
Recent News
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?
In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism
Amneal Pharmaceuticals is back in focus after analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models. Much of this shift lines up with Street research that leans positive on growth, execution, and the potential from new product launches and a broader portfolio. Keep reading to see what is changing in the narrative around Amneal Pharmaceuticals and how you can track those moving parts over time. Stay updated as the Fair Value for Amneal...
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.